EMGALITY

eli lilly canada inc🇨🇦 Health Canada

Approval Id: 6d81e6e0e11b9903
Drug Approval Canada Name: EMGALITY
Product Name: EMGALITY
Status: Marketed
Status Date: 2021-01-11
Original Market Date: 2021-01-11
Din: 02505134
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Subcutaneous
Schedule: Schedule D , Prescription
Ahfs: 28:32.12
Atc Original: N02CD02 GALCANEZUMAB
Atc Name: n 02 cd 02
Aig Number: 0161690002
Company Name: eli lilly canada inc
Company Address: SUITE 900, Exchange Tower, 130 King Street West, Toronto, Ontario, Canada, M5X 1B1

GALCANEZUMAB

100 MG / ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

6d81e6e0e11b9903

Type

Standard